R11 modified tumor cell membrane nanovesicle-camouflaged nanoparticles with enhanced targeting and mucus-penetrating efficiency for intravesical chemotherapy for bladder cancer

Zheng, Bin; Liu, Zhenghong; Wang, Heng; Sun, Li; Lai, Wing-Fu; Wang, Jinxue; Liu, Yang; Qin, Xiaowen; Qi, XiaoLong; Wang, Shuai; Shen, Youqing; Zhang, Pu; Zhang, Dahong

doi:10.1016/j.jconrel.2022.09.055

Cited by 25 publications

(20 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The intercellular structures that support direct transfer are tunnelling nanotubes (TNTs), which are membranous protrusions hanging over the substrate and connecting two adjacent cells. 11 Likewise, RP conjugates were colocalized with TNT-derived F-actin (Figure 3G) and the TNT-derived plasma membrane (Figure 3H) between donor and acceptor cells. The spatial correlation between RP conjugates and tubulin, another component of TNTs, was weak (Figure S5).…”

Section: ■ Introductionmentioning

confidence: 88%

A Selective-Tumor-Penetrating Strategy via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer

Qin,

Wang,

et al. 2024

J. Med. Chem.

Self Cite

View full text Add to dashboard Cite

A selective tumor-penetrating strategy generally exploits tumor-targeted ligands to modify drugs so that the conjugate preferentially enters tumors and subsequently undergoes transcellular transport to penetrate tumors. However, this process shields ligands from their corresponding targets on the cell surface, possibly inducing an off-target effect during drug penetration at the tumor-normal interface. Herein, we first describe a selective tumor-penetrating drug (R11-phalloidin conjugates) for intravesical therapy of bladder cancer. The intravesical conjugates rapidly translocated across the mucus layer, specifically bound to tumors, and infiltrated throughout the tumor via direct intercellular transfer. Notably, direct transfer from normal cells to tumor cells was unidirectional because the pathways required for direct transfer, termed F-actin-rich tunneling nanotubes, were more unidirectionally extended from normal cells to tumor cells. Moreover, the intravesical conjugates displayed strong anticancer activity and well-tolerated biosafety in murine orthotopic bladder tumor models. Our study demonstrated the potential of a selective tumor-penetrating conjugate for effective intravesical anticancer therapy.

show abstract

Section: ■ Introductionmentioning

confidence: 88%

A Selective-Tumor-Penetrating Strategy via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer

Qin,

Wang,

et al. 2024

J. Med. Chem.

Self Cite

View full text Add to dashboard Cite

show abstract

“…However, the low stability of noncovalent binding through electrostatic interaction may impact the efficacy of this method. [ 22 ]…”

Section: Cmn Surface Engineering Strategymentioning

confidence: 99%

Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy

et al. 2023

View full text Add to dashboard Cite

The advent of immunotherapy has marked a new era in cancer treatment, offering significant clinical benefits. Cell membrane as drug delivery materials has played a crucial role in enhancing cancer therapy because of their inherent biocompatibility and negligible immunogenicity. Different cell membranes are prepared into cell membrane nanovesicles (CMNs), but CMNs have limitations such as inefficient targeting ability, low efficacy, and unpredictable side effects. Genetic engineering has deepened the critical role of CMNs in cancer immunotherapy, enabling genetically engineered‐CMN (GCMN)‐based therapeutics. To date, CMNs that are surface modified by various functional proteins have been developed through genetic engineering. Herein, a brief overview of surface engineering strategies for CMNs and the features of various membrane sources is discussed, followed by a description of GCMN preparation methods. The application of GCMNs in cancer immunotherapy directed at different immune targets is addressed as are the challenges and prospects of GCMNs in clinical translation.

show abstract

“…They help increase the efficiency of chemotherapy for BC by regulating drug release, so extending the length of action, lowering the risk of adverse effects, and allowing the wrapping of numerous medicines 150–152 . Hence, therapeutic efficacy is enhanced by well‐designed nanoparticles due to increased penetration efficiency 153 . Some research has also centered on the issue of drug resistance developing during chemotherapy for BC.…”

Section: Using Nanomedicine For Bladder Cancer Therapymentioning

confidence: 99%

“…[150][151][152] Hence, therapeutic efficacy is enhanced by well-designed nanoparticles due to increased penetration efficiency. 153 Some research has also centered on the issue of drug resistance developing during chemotherapy for BC. Postoperative chemotherapy for BC, which is currently being studied at an increasing rate, is thought to dramatically lower the F I G U R E 7 Current bladder cancer therapies.…”

Section: Using Nanomedicine For Bladder Cancer Therapymentioning

confidence: 99%

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Sharma,

Malviya

2023

Precision Medical Sciences

View full text Add to dashboard Cite

Bladder cancer (BC) accounts for roughly 3% of all cancer diagnoses in developed countries. The prognosis could be improved significantly if the cancer is detected and classified as either muscle‐invasive bladder cancer (MIBC) or non‐muscle‐invasive bladder cancer (NMIBC) as promptly as possible. A potential ray of hope for the treatment of BC has emerged with the rapid development of nanomedicine and microRNAs (miRNAs), which promise to have fewer adverse effects, more tumor‐inhibitory effects, and decreased drug resistance. The complex interplay between hereditary and environmental variables is the root cause of this malignancy. Gene expression can be regulated by miRNAs, which are small, non‐coding RNAs that can either prevent the translation of protein‐coding genes or cleave RNA transcripts at certain locations. Elevated genomics has enabled a more extensive investigation of miRNAs whose expression is considerably different in BC patients compared to healthy volunteers or between BC tumor tissues and peripheral tissues. miRNAs have recently been discovered to be important regulators of BC cell carcinogenicity. Inaccurate diagnoses and prolonged treatment delays are more likely to occur due to the current diagnostic process such as lack of sensitivity and specificity and poor image quality. Patients now have access to a plethora of treatment options, including but not limited to surgery, chemotherapy, immunotherapy, gene therapy, and other innovative medicines, and in some cases, combination therapies. BC is one of the deadliest and most disabling malignancies affecting the urinary tract. Cancer of the urinary bladder has a terrible propensity for being fatal. BC is an intricate illness whose development can be affected by multiple parameters. Standard treatments for BC increase prognosis and survival, although recurrence is a major concern for patients. miRNAs are naturally occurring, small RNA molecules that have been linked to cancer through their expression being dysregulated. miRNAs modulate many cellular activities including proliferation, migration, differentiation, and apoptosis. MiRNA dysregulation is recognized in BC, and miRNAs are used as diagnostic and prognostic indicators. However, this manuscript discusses the recent progress made in nanomedicine and the function of miRNAs in the pathogenesis and targeted therapy of BC.

show abstract

R11 modified tumor cell membrane nanovesicle-camouflaged nanoparticles with enhanced targeting and mucus-penetrating efficiency for intravesical chemotherapy for bladder cancer

Cited by 25 publications

References 39 publications

A Selective-Tumor-Penetrating Strategy via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer

A Selective-Tumor-Penetrating Strategy via Unidirectional Direct Transfer for Intravesical Therapy of Bladder Cancer

Genetically Engineered‐Cell‐Membrane Nanovesicles for Cancer Immunotherapy

miRNAs involvement in the etiology and targeted therapy of bladder cancer: Interaction between signaling pathway

Contact Info

Product

Resources

About